| Identification | Back Directory | [Name]
Hexadecanamide, N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]- | [CAS]
245329-78-6 | [Synonyms]
EtDO-P4
N-[(1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]hexadecanamide
Hexadecanamide, N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]- | [Molecular Formula]
C31H52N2O4 | [MDL Number]
MFCD11616162 | [MOL File]
245329-78-6.mol | [Molecular Weight]
516.76 |
| Chemical Properties | Back Directory | [Boiling point ]
684.4±55.0 °C(Predicted) | [density ]
1.050±0.06 g/cm3(Predicted) | [storage temp. ]
-10 to -25°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [pka]
13.45±0.20(Predicted) | [color ]
White to off-white | [InChIKey]
BBTZZVJOQCCAOR-DLFZDVPBSA-N | [SMILES]
N3(CCCC3)C[C@@H](NC(=O)CCCCCCCCCCCCCCC)[C@H](O)c1cc2c(cc1)OCCO2 |
| Hazard Information | Back Directory | [Uses]
EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma[1]. | [Biological Activity]
EtDO-P4a ceramide analogis a cell penetrantpotent and selective nanomolar inhibitor of UDP-glucose ceramide glucosyltransferase (UGCG). Inhibition of UGCG by EtDO-P4 decreases drug resistance and enhances cytotoxicity of chemotherapeutic drugs such as vincristinedaunorubicinLucena-1 and cisplatin. | [References]
[1] Seung-Yeol Park, et al. Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor. Biochim Biophys Acta. 2012 Jul;1820(7):1141-8. DOI:10.1016/j.bbagen.2012.04.008 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|